Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population

Xijing Hospital100 enrolled

Overview

The purpose of this study is to evaluate the immunogenicity and immune protection of COVID-19, especially the recently prevalent strains, against the background of current immunization in Chinese population

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

COVID

Interventions

No InterventionsOTHER

No intervention

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. He was infected with COVID-19 from November to December 2022; 2. Have not been infected with COVID-19 (the subject said that he was not infected and signed the informed consent form); 3. Those who agree and sign the informed consent form. Exclusion Criteria: 1. Missing or incomplete questionnaires that affect research results; 2. Individuals with combined dysfunction of important organs such as the heart, liver, and lungs; 3. Mental and behavioral abnormalities; 4. Intellectual disability; 5. Under 18 years old or over 75 years old; 6. Low understanding and communication skills.

Locations (1)

The First Affiliated Hospital of Air Force Military Medical University

Xi'an, Shaanxi, China

Outcomes

Primary Outcomes

PBMC

When conducting blood sample analysis, we focus on separating and evaluating in detail the composition and counting of peripheral blood mononuclear cell (PBMC). This process involves identifying and quantifying various types of mononuclear cells in the sample, such as lymphocytes, monocytes, etc. These cells are crucial for understanding an individual's immune status. Through precise separation techniques and advanced cell analysis methods, we are able to obtain accurate and detailed reports on the classification and quantity of mononuclear cells.

Time frame: About two and a half years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.